OGT and cancer: Thus, manipulation of O-GlcNAc levels using chemical or shRNA-mediated inhibition of OGA or OGT affects in vitro and in vivo migration/invasion of breast (31, 112, 121), lung (31, 33), liver (34), prostate (37), and colon (33) cancer cells.